BiotechTube
Curatis

Curatis

CURN.SW
Zug, Switzerland· Est.
curatis.ch
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

CURN.SW · Stock Price

CHF 23.50+12.95 (+122.75%)
Market Cap: $152.4M

Historical price data

Overview

Curatis is a Swiss public biotech focused on developing innovative therapeutics for rare diseases and oncology. Its core asset is a proprietary technology platform designed to identify novel targets and generate optimized drug candidates. The company's strategy centers on advancing its clinical-stage programs, CUR-001 and CUR-002, through proof-of-concept while expanding its preclinical pipeline. With a modest market valuation, Curatis represents a high-risk, high-reward investment opportunity in the specialized European biotech sector.

OncologyAutoimmune Disorders

Technology Platform

A proprietary, integrated drug discovery platform designed to identify novel biological targets and generate optimized therapeutic candidates, potentially including biologics and small molecules, for complex diseases.

Funding History

1
Total raised:$25M
IPO$25M

Opportunities

The rare disease and targeted oncology markets offer accelerated regulatory pathways and premium pricing.
Positive clinical data from its lead Phase 2 program could trigger significant partnership interest and valuation inflection.
The proprietary platform provides a long-term engine for pipeline growth beyond the current assets.

Risk Factors

High risk of clinical trial failure inherent to all drug development.
Pre-revenue status and low market cap create severe financing risk and dependence on positive data to raise capital.
Intense competition in both autoimmune and oncology spaces from larger, better-funded entities.

Competitive Landscape

Faces intense competition from hundreds of biotech firms and large pharma in both rare diseases and oncology. Differentiation requires clear clinical superiority or a novel mechanism of action. As a small, public Swiss biotech, it also competes for investor capital and partnership deals in a crowded sector.

More companies in Switzerland →